ATS 2024 Final Program

Click on the session title to view the speakers

200

MONDAY • MAY 20

• understand the current state of screening for ILD in CTD and integrate new ACR guidelines into current practice • describe the current utility and limitations of clinical, blood-based, and radiomic biomarkers in CTD-ILD diagnosis and and understand how to incorporate these biomarkers in clinical decision-making • better counsel patients on management options after early diagnosis of CTD-ILD Interstitial lung disease (ILD) is a serious complication of connective tissue disease (CTD), leading to significant morbidity and mortality. With several therapeutics known to improve outcomes, early recognition is critical. While HRCT is the current gold standard for diagnosis, it is not universally utilized as a screening tool in all high-risk patients. This symposium will review the current state of screening for CTD-ILD, highlight the 2023 American College of Rheumatology ILD Guidelines, explore the application of clinical, blood-based, and radiomic biomarkers, and review interventions after early CTD-ILD diagnosis. This multi-disciplinary panel comprises pulmonologists, rheumatologists, and radiologists. 2:15 Introduction and Overview 2:18 Patient Speaker 2:23 Current State of CTD-ILD Screening and Diagnosis 2:38 Question and Answer 2:43 Radiomics in CTD-ILD 2:58 Question and Answer 3:03 Clinical and Blood-Based Biomarkers of CTD-ILD 3:18 Question and Answer 3:23 Management Decisions After Early Detection of CTD-ILD 3:38 Question and Answer This session and the International Conference are supported

CLINICAL CLINICAL TOPICS IN PULMONARY MEDICINE B83 ARTIFICIAL INTELLIGENCE IN THE RADIOLOGICAL ASSESSMENT OF INTERSTITIAL LUNG DISEASE Assemblies on Clinical Problems; Pulmonary Circulation 2:15 p.m. - 3:45 p.m. San Diego Convention Center Room 6B (Upper Level) Target Audience General and ILD Pulmonologists and Radiologists Hospital administrators considering whether to invest in novel technology. Clinical trialists, the pharmaceutical industry and representatives from the FDA and NIH Trainees and Fellows Objectives At the conclusion of this session, the participant will be able to: • better understand the limitations associated with current radiological tools used for assessing patients with interstitial lung disease both in terms of diagnosis and prognostication and the opportunities which novel imaging techniques may hold • better understand the different AI scientific approaches applied to CT scans in patients with interstitial lung disease • develop a nuanced appreciation for the challenges associated with approval of new therapies using existing clinical trial end points and the opportunities which AI derived imaging biomarkers hold This session will provide a cutting-edge update on the role of AI in the radiological assessment of ILD by exploring the new available technology and different scientific approaches employed. We will review the published literature and the emerging opportunities. We will evaluate the potential role of AI to expedite the diagnosis of ILD and to prognosticate from a baseline CT scan stratifying patients with the goal of earlier diagnosis and treatment. We will explore the barriers to adoption of novel technology in routine healthcare and regulatory challenges to establishing novel clinical trial endpoints to facilitate the approval of new therapies. 2:15 Introduction to the Symposium 2:17 Current Perspectives on the Use of AI and Machine Learning in the Diagnosis and Management of Fibrotic Lung Disease 2:32 The Quest to Dig Deeper into a CT Scan of the Chest

by an independent medical educational grant from Boehringer IngelheimPharmaceuticals, Inc.

All CMEsessions have been planned and implemented in accordancewith the AccreditationCriteria of theAccreditationCouncil for ContinuingMedical Education (ACCME ® ) and are free of the control of ineligible companies (formerly commercial interests).

ATS 2024 Conference Program • San Diego, CA